Zacks Research Issues Positive Outlook for PAHC Earnings

Phibro Animal Health Corporation (NASDAQ:PAHC) – Stock analysts at Zacks Research increased their Q3 2027 earnings estimates for shares of Phibro Animal Health in a research note issued on Friday, October 23rd. Zacks Research analyst Team now expects that the company will post earnings of $0.83 per share for the quarter, up from their prior forecast of $0.82. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Phibro Animal Health’s current full-year earnings is $3.49 per share. Zacks Research also issued estimates for Phibro Animal Health’s FY2027 earnings at $3.47 EPS, Q1 2028 earnings at $0.84 EPS, FY2028 earnings at $3.66 EPS and FY2029 earnings at $3.88 EPS.

Phibro Animal Health (NASDAQ:PAHC) last posted its earnings results on Wednesday, August 26th. The company reported $0.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.71 by $0.14. The company had revenue of $396.75 million for the quarter, compared to analysts’ expectations of $381.18 million. Phibro Animal Health has set its FY 2027 guidance at 3.410-3.590 EPS.

Separately, Weiss Ratings reissued a “hold (c+)” rating on shares of Phibro Animal Health in a report on Friday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $47.67.

Phibro Animal Health Trading Down 1.7%

NASDAQ:PAHC opened at $38.38 on Monday. Phibro Animal Health has a 52-week low of $28.25 and a 52-week high of $60.08. The business’s fifty day moving average is $36.79 and its 200 day moving average is $41.13.

Institutional Trading of Phibro Animal Health

A number of hedge funds and other institutional investors have recently bought and sold shares of PAHC. Baird Financial Group Inc. lifted its stake in Phibro Animal Health by 2.7% in the 2nd quarter. Baird Financial Group Inc. now owns 10,710 shares of the company’s stock worth $336,000 after purchasing an additional 279 shares in the last quarter. Cetera Investment Advisers boosted its holdings in Phibro Animal Health by 2.7% in the 1st quarter. Cetera Investment Advisers now owns 10,997 shares of the company’s stock valued at $608,000 after purchasing an additional 293 shares during the period. Smith Group Asset Management LLC grew its position in shares of Phibro Animal Health by 1.7% during the 3rd quarter. Smith Group Asset Management LLC now owns 25,846 shares of the company’s stock valued at $924,000 after purchasing an additional 439 shares in the last quarter. KBC Group NV purchased a new position in shares of Phibro Animal Health during the 1st quarter valued at $29,000. Finally, Sterling Capital Management LLC grew its position in shares of Phibro Animal Health by 864.9% during the 3rd quarter. Sterling Capital Management LLC now owns 714 shares of the company’s stock valued at $26,000 after purchasing an additional 640 shares in the last quarter. Institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation develops, manufactures and sells products designed to support the health, nutrition and productivity of food-producing animals. Its offerings include animal health products, vaccines, medicated feed additives, nutritional specialties and performance products used in livestock, poultry and aquaculture.

The company’s products are intended to help prevent and manage disease, improve animal well-being and support efficient food production. Phibro serves producers, veterinarians, feed manufacturers and distributors through a portfolio that includes pharmaceuticals, vaccines, mineral and nutritional supplements, and other feed and water solutions.

Phibro Animal Health markets its products internationally across a broad range of geographic regions, including North America, Latin America, Europe, Asia-Pacific and other global markets.